Introduction
The dystonias are a diverse collection of movement disorders arising from different etiologies that lead to characteristic patterns of involuntary muscle contractions and twisted postures (Albanese et al., 2013a) . Most cases in which dystonia is the primary clinical manifestation appear to have a genetic predisposition, with over 25 gene loci linked to different forms of the disease (Lohmann and Klein, 2013) Schneider et al., 2009; Schneider and Bhatia, 2010 ). Yet in no form of hereditary dystonia is a connection to PD more apparent than in X-linked DystoniaParkinsonism (XDP, DYT3, OMIM #3142590), a progressive neurodegenerative disease endemic to the island of Panay, Philippines (Lee et al., 2011) . XDP follows an unusual clinical course, consisting primarily of dystonic symptoms at early disease stages that shift over time towards a more parkinsonian phenotype (Lee et al., 2002; Lee et al., 2011) . The underlying disease mechanisms and pathogenic substrates are not clear, but neuropathological studies indicate that XDP involves a progressive loss of medium spiny neurons in the striatum (Waters et al., 1993; Goto et al., 2005) and decreased numbers of neural progenitor cells within the subventricular zone (Goto et al., 2013) .
Previous genetic linkage (Wilhelmsen et al., 1991; Kupke et al., 1992; Graeber et al., 1992) and association (Müller et al., 1994; Haberhausen et al., 1995; Németh et al., 1999 ) studies mapped the XDP founder haplotype to a region of chromosome Xq13.1 that was recently narrowed further to an interval of approximately 294 kb (Domingo et al., 2015) . The region contains five known genes, NONO, TAF1, OGT, ACRC and CXCR3, as well as an intergenic Multiple Transcript System (MTS) comprised of five unconventional exons (Nolte et al., 2003; Herzfeld et al., 2007; Domingo et al., 2015) .
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Sequencing of this region revealed seven XDP-specific sequence variants: five diseasespecific single nucleotide changes (designated DSC-1,-2,-3,-10, and -12), a 48 bp deletion, and an SVA (SINE-VNTR-Alu)-type retrotransposon insertion (Nolte et al., 2003; Makino et al., 2007) . Only one variant, DSC3, falls within a potential coding region, introducing a single nucleotide substitution in one of the MTS exons (Nolte et al., 2003) . The other variants are localized either within TAF1 introns or the intergenic region containing the MTS which is 3' to exon 38 of TAF1. To date it has not been possible to exclude any of these variants as pathogenic, as extensive genotyping of large numbers of XDP individuals and ethnically-matched control subjects has detected all markers in essentially all cases; the few exceptions, which were negative for all markers, were considered likely phenocopies (Domingo et al., 2015) .
Of the five known genes within this interval, TAF1 has arguably received the most attention as the one likely to be responsible for XDP pathogenesis. TAF1 is a large gene with at least 38 exons which encodes a transcription factor, TATA-Binding Protein-Associated Factor-1 (TAF1), which is part of the transcription factor IID (TFIID) complex involved in RNA polymerase II-mediated transcription (Ruppert et al., 1993; Thomas and Chiang 2006) . The hypothesis that TAF1 may be the culprit in XDP has been based in part on the relationship of the XDP sequence variants to its genomic structure and transcripts. Three of the haplotype markers (DSC10, -12, and the SVA) alter sequences within TAF1 introns, and RNAs derived from MTS exons can reportedly splice to various TAF1 transcripts (Nolte et al., 2003; Herzfeld et al., 2007; Makino et al., 2007) . In addition, a previous study identified a neural-specific TAF-1 isoform, N-TAF1, which appeared significantly downregulated in XDP caudate relative to control brain tissue (Makino et al., 2007) . N-TAF1 utilizes an alternative exon, 34', of only six nucleotides, which adds an alanine and lysine to the encoded protein (Makino et al., 2007; Sako et al., 2011; Jambaldorj et al., 2012) . It has been suggested that the decreased expression of N-TAF1 may be the result of the 2.6 kb SVA insertion within intron 32 of TAF1 (Makino et al., 2007) . However, it is not clear how this insertion acts to interfere with transcription of N-TAF1.
In this study we generated XDP and matched control induced pluripotent stem cell (iPSC) lines which can be differentiated into neural cells in order to establish a model system for probing cellular defects associated with the disease. Towards that end, we Disease Models & Mechanisms • DMM • Advance article derived fibroblasts from confirmed XDP individuals and unaffected family members as matched control subjects, reprogrammed these cells to iPSCs, and then re-differentiated iPSCs to generate XDP and control neural stem cells (NSCs). As a first application of this model, we assayed expression of TAF1 and MTS-derived transcripts in both the iPSC-derived NSCs as well as the parent fibroblast lines. These analyses revealed genotypic differences in the expression of multiple TAF1 transcripts in fibroblasts and decreased expression of N-TAF1 in XDP vs. control NSCs. These findings are consistent with the previous report of an XDP-related defect in N-TAF1 expression (Makino et al., 2007) , indicating that the patient iPSC-derived neural cells recapitulate a phenotype detected in patient post-mortem brain tissue. In addition, the present results further suggest that this defect may not be solely associated with advanced disease stages but may instead occur in XDP neural cells at early stages that precede the development of neuronal cell death.

RESULTS
Clinical characteristics and genotype of XDP individuals
Of the five XDP individuals that participated in this study, only one (32517 ; Table 1) was examined prior to undergoing deep brain stimulation (DBS). At the time of fibroblast derivation, this subject presented with segmental dystonia affecting the jaw and larynx. Dystonic symptoms subsequently worsened and generalized to other muscle groups over the course of one year, at which point the patient underwent bilateral pallidal DBS. The other four subjects had similar clinical histories, involving initial onset of dystonic symptoms in various muscle groups. At the time of skin biopsy, these subjects exhibited variable degrees of dystonia, ranging from generalized symptoms affecting the left hand, torso and left leg in one subject (34363) to focal neck dystonia in another (33109). Bradykinesia without rigidity was a common feature among subjects. All control family members showed no neurological abnormalities upon examination.
Genotypes of affected individuals and control family members were determined via PCR for six of the seven reported haplotype markers (Nolte et al., 2003; Makino et al., 2007) . The five single nucleotide substitutions (DSC1, -2, -3, -10, and -12) were evaluated by PCR amplification followed by Sanger sequencing of the products. The affected subjects showed a consistent pattern, with the same nucleotide substitutions at each DSC that had been previously associated with XDP (Table 2) . The control individuals all had wild-type sequences at each site. The 2.6 kB SVA retrotransposon was detected by long-range PCR amplification using primers flanking the insertion site.
A single PCR product was detected in both XDP and control samples, which differed in size by approximately 2.6 kB (0.6 kb in control vs. 3.2 kb in XDP samples), consistent with the size of the SVA (Fig. 1A ). There were no genotypic differences noted in growth rate or cell division among the fibroblast lines. As expected, fibroblasts from the older donors, 33808 (XDP) and 33809 (control), had decreased doubling times in culture compared to the lines derived from younger subjects. However, most of the lines grew at comparable rates, and all fibroblast experiments were performed at equivalent early passages.
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Analysis of TAF1 and MTS transcripts in fibroblasts
We compared expression of transcripts derived from TAF1 and the putative MTS exons in XDP vs. control fibroblasts using a panel of previously described primers (Makino et al., 2007) interrogating 21 mRNAs (Fig. 1B-C) . Of the 21 transcripts assayed, seven were undetectable in both patient and control fibroblast samples. The panel included six primer sets targeting transcripts that reportedly incorporate MTS sequences, either alone (MTS-2/3, MTS-3/4, MTS-V4) or spliced to exons of TAF1 (MTS-32'/34', MTS-37/1, MTS-37/3) (Makino et al., 2007) . None of these mRNAs appeared to be expressed in fibroblasts. In addition, primer set TA14-391, which was previously shown to be specific to the neural TAF1 isoform, N-TAF1, did not detect a product in fibroblasts.
Among the remaining 14 mRNAs tested, five showed differential expression distinguishing XDP from control samples at p < 0.05 (Fig. 1B) . Three primer sets (TAF1-3', TA14-385N, and TAF1-3'N) amplified transcript fragments derived from exons 32-36 which were significantly decreased in XDP fibroblasts compared to control cells. These exons flank the SVA insertion in intron 32 and span the region containing the alternative exon, 34', from which the neural isoform, N-TAF1, is generated. Other primers within the panel also targeted fragments derived from these exons; although levels of their respective products were also lower in XDP cells relative to controls, the differences did not achieve statistical significance. Two other transcript fragments showed significant differences in expression in XDP vs. control cells: one fragment (amplified by TA02-334) derived from exons 4-5 had lower levels in XDP cells, and another (from TA09-693) incorporating sequences from exons 19-21 had higher expression in XDP cells than in controls. In addition to TAF1 transcripts, we also assayed expression of three genes also contained within the XDP genomic region (CXCR3, ACRC, and OGT) but none showed differential expression in patient vs. control fibroblasts (supplementary material Fig. S1 ).
In other genes, SVA insertions have been shown to generate aberrant transcripts consisting of retrotransposon sequences spliced to RNA derived from the surrounding exons (Hancks and Kazazian, 2012) . To probe for such exonization of the SVA in TAF1, we designed two additional primer sets flanking the insertion (Table S1) were cultured in a specific NMD inhibitor, NMDI14 (Martin et al., 2014) , prior to RNA isolation and reverse transcription. Gel electrophoresis of the PCR products showed bands of equivalent sizes in XDP and control samples (supplementary material Fig. S2 ), suggesting that SVA sequences were not incorporated into these particular transcript fragments.
The observation that N-TAF1 was not detectable in fibroblast RNA appears consistent with its previously documented pattern of neural tissue-specific expression (Makino et al., 2007; Sako et al., 2011; Jambaldorj et al., 2012) . As additional validation, we used the TA14-391 primer set to assay N-TAF1 transcript levels in RNA obtained from SH-SY5Y human neuroblastoma cells, as well as human brain. Moderate N-TAF1 transcript expression was detected in SH-SY5Y cells, which increased slightly in cells differentiated in all-trans-retinoic acid (ATRA) for 72 h (Table 3) . N-TAF1 expression in human brain was considerably higher, representing a more than 60-fold increase above the levels detected in undifferentiated SH-SY5Y cells.
Generation of iPSCs and neural conversion
Given previous data specifically implicating N-TAF1 in XDP pathogenesis (Makino et al., 2007) , a major objective of this study was to generate XDP cell lines in which expression of this variant could be further examined. Towards that end, we reprogrammed five XDP and four control fibroblasts to iPSCs that could be redifferentiated into neural cells. Reprogramming was accomplished via non-integrating Sendai virus. Control fibroblast 33809 exhibited slow growth in culture and typically underwent senescence at lower passages than the other cell lines, making it difficult to expand sufficiently for viral inoculation. Given that fibroblast growth rate can greatly influence reprogramming efficiency (Hanna et al. 2010) , this cell line was not reprogrammed. All of the XDP fibroblasts and three of the control lines (33113, 33114, and 33362) generated at least two iPSC clones each which exhibited significant upregulation of pluripotency-related genes, Dmnt3b, hTERT, Nanog, Oct4, Rex1, and Sox2, compared to the parent fibroblast lines, as measured by qRT-PCR ( To quantify functional pluripotency of each iPSC line, embryoid bodies (EB) were generated in culture from all clones and assayed for expression of germ layer marker genes via the Taqman® hPSC Scorecard™ Assay (Bock et al., 2011; Tsankov et al., 2015) . As expected, the differentiated EBs exhibited little to no expression of genes involved in self-renewal but were positive for multiple markers of each lineage ( Fig.   3A ). There was some variability in expression of individual genes across the various clones, but the overall pattern was largely consistent and revealed no genotypic differences in pluripotency. Mesoderm-related genes appeared to be more highly expressed than markers of endoderm and ectoderm, but the observed signatures suggest that all clones retain the capacity to differentiate towards all three lineages. In parallel to the EB analysis, selected iPSC clones were also injected into mice to evaluate pluripotency in vivo. All clones tested formed teratomas containing cells representative of the three germ layers, based on morphology visible by Hematoxylin and Eosin (H&E) staining ( Fig. 3B-G ). The iPSC lines had comparable morphologies ( Fig. 4A) and growth behavior in culture, except for clone 33109-2G, which exhibited a high rate of spontaneous differentiation which interfered with propagation and prevented neural conversion. This behavior appeared to be a clone-specific property, as the companion line, 33109-2B, did not differ in its growth characteristics from the other iPSC lines.
All iPSC clones have been deposited at the repository at WiCell (Madison, WI; www.wicell.org) and are publicly available.
To generate NSCs, XDP and control iPSCs were cultured in PSC™ Neural Induction Medium for seven days, at which point they were replated on Geltrex-coated culture dishes and propagated in Neural Expansion Medium. For most of the iPSC lines, the neural induction protocol generated cells with characteristic NSC-like morphology ( 
Analysis of TAF1 and MTS transcripts in NSCs
We used the panel of primers interrogating TAF1 and MTS-derived mRNAs to compare transcriptional patterns in XDP and control NSCs. RNA was isolated from all NSC lines at passage 4 post-induction. As in the fibroblasts, the NSC lines did not appear to express any of the MTS-derived RNAs (Fig. 5A) . Unlike in fibroblasts, the N-TAF1 variant was expressed in NSCs at levels which were on average approximately 3-fold lower in XDP vs. control clones (p < 0.05; Fig. 5A ). Although multiple TAF1 fragments appeared differentially expressed in XDP vs. control fibroblasts (Fig. 1B) , N-TAF1 was the only transcript in this panel which distinguished patient from control NSCs. N-TAF1 utilizes an alternative exon, 34' (Fig. 1C) consisting of only six nucleotides that encode two additional residues, an alanine and a lysine, which become positions 1646-47, respectively, of an 1847-aa protein ( Fig. 5B ; Makino et al., 2007) .
The insertion is C-terminal to two tandem bromodomains which mediate histone interactions (Jacobsen et al., 2000) and immediately adjacent to a threonine, T1643,
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which is a potential phosphorylation site (Hornbeck et al., 2011) . These three residues, T1643, A1646, and K1647, fall within a short cluster of prolines which could potentially form a polyproline helix, although it is difficult to accurately predict such motifs in silico. The other notable feature of this segment is the preponderance of aspartate and glutamate residues that appear to make up an acidic tail. Aside from these limited observations, the protein sequence itself does not reveal potential function(s) of the N-TAF1-unique residues, and because the insertion falls within an intrinsically disordered region of the protein, structural analyses of this segment have not been possible (Jacobsen et al., 2000) . individuals; the latter group, thought to be phenocopies, were negative for all markers, similar to the control subjects (Domingo et al., 2015) . In this study, we genotyped six of the seven sequence variants and observed a similar "all or none" distribution in affected vs. unaffected family members. This inability to rule out any of the seven genomic variants has complicated efforts to understand XDP pathogenesis. That these sequence variants cluster around TAF1 and the intergenic MTS has focused most hypothesized disease models on their respective gene products, but critical questions remain unanswered. With respect to the MTS, it is noteworthy that it contains the only XDP sequence variant, DSC3, which alters a potential coding exon (Nolte et al., 2003; Herzfeld et al., 2007) . It should be noted that the lack of MTS expression in the cells profiled here does not in itself exclude the potential importance of these exons and/or DSC3 to XDP. It is still possible that these transcripts may be expressed at later neurodevelopmental stages and/or in specific neuronal subtypes that are involved in the disease process. Further studies will therefore be required to probe the possible contributions of these transcripts as well as the specific cellular pathways that may be affected by them and/or by decreased N-TAF1 expression. In that regard, the development of XDP patient-specific iPSC lines which can be differentiated toward specific neuronal cell fates in culture may be powerful tools that enable such investigations.
MATERIALS AND METHODS
XDP and control subjects
Subjects recruited for this study included: (1) Table S1 ) included previously published sequences (Nolte et al., 2003) , as well as novel primers generated using NCBI Primer-BLAST software.
PCR amplicons were resolved via gel electrophoresis, purified using QIAquick™ Gel
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Extraction kit (Qiagen), and sequenced to determine the presence or absence of XDPspecific nucleotide substitutions. To detect the SVA, long-range PCR was performed using previously described primers (Kawarai et al., 2013 ) and Takara's PrimeSTAR GXL DNA polymerase (Clontech, Mountain View, CA USA) with modified amplification conditions (Table S1 ). PCR amplicons were resolved via gel electrophoresis to identify either a 3229 bp product (XDP; containing the approximately 2.6 kb SVA) or a 599 bp product (control; no SVA).
iPSC reprogramming and confirmation of pluripotency
To generate iPSCs, XDP and control fibroblasts were seeded into 6-well plates at an approximate density of 1 x 10 5 cells/well in fibroblast growth medium.
Reprogramming was performed using the Cytotune™-iPS Reprogramming Kit (Life Geltrex was performed by initial digestion in Accutase, followed by scraping, as described above. Cell lines were routinely tested for contamination, including mycoplasma, and confirmed to be negative.
Neural differentiation
XDP and control iPSC colonies on Geltrex were dissociated in Accutase to single cells which were seeded into fresh coated plates at an approximate density of 2-3 for 20 minutes, rinsed 3X again in PBS, and then blocked in normal goat serum (10% in PBS) for 1 hr. Cells were incubated in primary antibodies at the specified dilution overnight at 4°C. The next day, slides were washed 3X in PBS, incubated in secondary antibodies for 45 min, and then counterstained (where indicated) for 15 minutes.
RT-PCR for TAF1 and MTS transcripts
To quantify expression of transcripts derived from exons 1-38 of TAF1, as well as the unconventional exons of the MTS (Nolte et al., 2003) , RT-PCR was performed using a panel of previously described primers (Makino et al., 2007) . RNA was extracted from XDP and control fibroblasts and iPSC-derived NSCs using Qiazol (Qiagen), then mixed with 1/5 th volume of chloroform with brief centrifugation to allow phase separation.
The aqueous phase was further processed using miRNeasy™ spin columns (Qiagen) with on-column DNAse digestion, as recommended. The resulting RNA samples were quantified via Nanodrop, and equivalent amounts were reverse transcribed using RT To probe for potential exonization of the SVA, cDNA samples from XDP cells were amplified with two sets of primers flanking the SVA insertion site (Table 1) DSC10  DSC1  DSC3  DSC2  32517  G  T  A  T  A  33109  G  T  A  T  A  33363  G  T  A  T  A  33808  G  T  A  T  A  34363  G  T  A  T  A  32643  T  C  T  C  G  33113  T  C  T  C  G  33114  T  C  T  C  G  33362  T  C  T  C  G  33809 T C T C G a DSC = disease-specific sequence change 
